Journal article
Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab
Abstract
RATIONALE: Clinical benefits of fixed-dose 100-mg subcutaneous (SC) mepolizumab in prednisone-dependent patients are modest when sputum eosinophilia is not adequately controlled.
OBJECTIVES: This study compared treatment response of weight-adjusted intravenous (IV) reslizumab in patients previously treated with 100-mg SC mepolizumab.
Authors
Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
Journal
American Journal of Respiratory and Critical Care Medicine, Vol. 197, No. 1, pp. 38–46
Publisher
American Thoracic Society
Publication Date
January 1, 2018
DOI
10.1164/rccm.201707-1323oc
ISSN
1073-449X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAntibodies, Monoclonal, HumanizedAsthmaBody WeightDose-Response Relationship, DrugDrug Administration ScheduleEosinophilsFemaleFollow-Up StudiesHumansInjections, IntravenousInjections, SubcutaneousMaleMiddle AgedProspective StudiesRisk AssessmentSeverity of Illness IndexStatistics, NonparametricTreatment Outcome